340736-74-5

Basic information

• Product Name: methyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoate
• Synonyms: methyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoate
• CAS NO: 340736-74-5
• Molecular Weight: 272.183
• Mol File: 340736-74-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 312.0±52.0 °C(Predicted)
• Density: 1.393±0.06 g/cm3(Predicted)
• CAS DataBase Reference: methyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoate(340736-74-5)
• EPA Substance Registry System: methyl 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoate(340736-74-5)

Safety Data

• Hazardous Substances Data: 340736-74-5(Hazardous Substances Data)

Upstream product

• 619-65-8 4-cyanobenzoic Acid 
• 65695-05-8 methyl 4-(N’-hydroxycarbamimidoyl)benzoate 
• 407-25-0 trifluoroacetic anhydride 
• 1129-35-7 4-cyanobenzoic acid methyl ester 
• 184778-33-4 methyl (Z)-4-(N’-hydroxycarbamimidoyl)benzoate 

Downstream Products

• 340736-76-7 4-[5-(trifluoromethyl)-1,.2,4-oxadiazol-3-yl]benzoic acid 
• 340736-48-3 methyl 2-[(2S)-4-[2-(tert-butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzoyl]amino]propanoyl]-3-oxopiperazinyl]acetate 

Relevant articles and documents

NOVEL OXADIAZOLES

The present invention relates to novel oxadiazoles of Formula I, wherein, R1, L1, A, L2 and R10 are as defined in the detailed description.

Orally active GPIIb/IIIa antagonists: Synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3- (2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic acid

To improve the in vivo potency of the potent GPIIb/IIIa antagonist 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3- (2-methoxy-2-oxoethyl)-2-oxopiperazinyl]lacetic acid (4), the amidino group was converted to an oxadiazole ring, thiadiazole ring of substituted amidoxime group. These groups were expected to be metabolized to an amidino group in vivo. The compounds synthesized were evaluated for their potency to inhibit the ex vivo adenosine 5′-diphosphate (ADP)-induced aggregation of guinea pig platelets. Among the compounds examined, the methoxycarbonyloxyamidine 8a exhibited the most potent ex vivo inhibitory activity with a fast onset and prolonged duration of action after oral administration.